转移性结直肠癌分子靶向治疗的策略和思考  

Strategy and Hypothesis of Molecular Targeted Therapy for Metastatic Colorectal Cancer

作　　者：陈佳艳[1] 唐曦[1] 

机构地区：[1]复旦大学附属华东医院肿瘤科,200040

出　　处：《胃肠病学》2016年第6期321-325,共5页Chinese Journal of Gastroenterology

摘　　要：结直肠癌是最常见的恶性肿瘤之一，转移性结直肠癌预后较差，单纯化疗的总生存期仅为1—1．5年。近年来，以血管内皮生长因子和表皮生长因子受体为作用靶点的分子靶向治疗已在临床上广泛用于治疗转移性结直肠癌，并且成为近期研究的热点。本文就转移性结直肠癌分子靶向治疗的策略展开思考。Colorectal cancer is one of the most commonly seen malignant tumors, and the metastatic colorectal cancer is of poor prognosis. The median overall survival for chemotherapy is only 1-1.5 years. Recently, molecular targeted therapy targeting at vascular endothelial growth factor and epidermal growth factor receptor was used widely for metastatic colorectal cancer and becoming a hot spot of related researches. This article focused on the strategy and hypothesis of molecular targeted therapy for treatment of metastatic colorectal cancer.

关 键 词：结直肠肿瘤 肿瘤转移 分子靶向治疗 血管内皮生长因子类 受体 表皮生长因子 

分 类 号：R735.34[医药卫生—肿瘤]